Martin de Kort is Scientific Lead Medicines Development at EATRIS, with more than 25 years of experience in life sciences R&D, the (bio)pharmaceutical industry, and academic research. After completing his PhD in bio-organic chemistry at Leiden University, he joined Organon, where he worked on novel thrombosis treatments up to clinical proof-of-concept. He then became Lead Optimization (LO) Project Manager at Schering-Plough, leading programmes on gut hormones for metabolic disease (insulin, incretins), applying proprietary technology to extend duration of action. Under Merck, he co-led LO teams in endocrinology, focusing on diabetes and fertility.

In 2012, Martin joined EATRIS, where he helped develop the organisation’s scientific platforms and novel models of public-private collaboration, including managing the molecular imaging hub with GlaxoSmithKline (GSK) for eight years. More recently, as Scientific Officer, he has been instrumental in launching flagship initiatives such as REMEDi4ALL, which is building a sustainable, accessible European platform for drug repurposing. Since 2023, he has also served on advisory boards and scientific evaluation panels for charities, funding bodies, and research institutions in translational research.